In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?
With an 83% reduction in the risk of disease recurrence in early-stage lung cancer, Astrazeneca’s Tagrisso takes the top spot at Asco.
June will be hectic for the US regulator, with many approval decisions due, including one for subcutaneous Arzerra in multiple sclerosis and Tazverik in follicular…
The Merck KGaA/Pfizer drug is said to have cured 52% of women with a rare gynaecological cancer, one of whom subsequently gave birth.
The green light comes two months early, revealing data that were being held back for Asco, but what does Yervoy bring to the table?
Arcus insists that its new partnership is a good deal, but shareholders make their feelings known.
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
A new mechanism for certain autoimmune conditions takes a big step forward with impressive pivotal data on Argenx’s efgartigimod.
Merck might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Speculation that Sanofi is gearing up for acquisitions could grow after it banks billions from its Regeneron stake sale.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
Filgotinib’s mixed efficacy in ulcerative colitis prompts a shares slide.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
An unexpectedly broad prostate cancer label gives the Parp inhibitor a strong advantage over Clovis’s rival Rubraca.
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Clinical data are expected soon from Novo Nordisk, Bayer and Sanofi, while Roche and Gilead take aim at ulcerative colitis.